NH-sulfoximine: A novel pharmacological inhibitor of the mitochondrial F 1 F o -ATPase, which suppresses viability of cancerous cells.
Autorzy:
Strobbe D; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy. Pecorari R; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy. Conte O; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy. Minutolo A; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research (CfMR), University College London, London, UK. Hendriks CMM; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany. Wiezorek S; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany. Faccenda D; Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, London, UK. AbetiR; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square London, London, WC1N 3BG, UK. Montesano C; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy. Bolm C; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany. Campanella M; Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, London, UK.; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research (CfMR), University College London, London, UK.; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2021 Jan; Vol. 178 (2), pp. 298-311. Date of Electronic Publication: 2020 Dec 14.
Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.
Autorzy:
AbetiR; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK. Zeitlberger A; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK. Peelo C; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK. Fassihi H; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK. Sarkany RPE; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK. Lehmann AR; Genome Damage and Stability Centre, University of Sussex, Brighton, UK. Giunti P; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK.; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2019 Nov; Vol. 176 (22), pp. 4293-4301. Date of Electronic Publication: 2019 Jan 23.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
